Precision Oncology with Drugs Targeting the Replication Stress, ATR, and Schlafen 11
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Precision Oncology with Drugs Targeting the Replication Stress, ATR, and Schlafen 11
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 18, Pages 4601
Publisher
MDPI AG
Online
2021-09-15
DOI
10.3390/cancers13184601
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer
- (2021) Pietro Paolo Vitiello et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma
- (2021) Raelene Endersby et al. Science Translational Medicine
- A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors
- (2021) Noboru Yamamoto et al. INVESTIGATIONAL NEW DRUGS
- Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development
- (2021) Fumiya Moribe et al. PLoS One
- Enhanced cytarabine-induced killing in OGG1-deficient acute myeloid leukemia cells
- (2021) Nichole Owen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors
- (2021) Ukhyun Jo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Schlafen 11 predicts response to platinum-based chemotherapy in gastric cancers
- (2021) Tsuyoshi Takashima et al. BRITISH JOURNAL OF CANCER
- Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress
- (2021) Anish Thomas et al. CANCER CELL
- SLFN11 inactivation induces proteotoxic stress and sensitizes cancer cells to ubiquitin activating enzyme inhibitor TAK-243
- (2021) Yasuhisa Murai et al. CANCER RESEARCH
- Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study
- (2021) Lauren Averett Byers et al. CLINICAL CANCER RESEARCH
- Regulation of DNA Replication Licensing and Re-Replication by Cdt1
- (2021) Hui Zhang INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers
- (2021) Bingnan Zhang et al. BRITISH JOURNAL OF CANCER
- ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer
- (2021) Ah-Rong Nam et al. CANCER LETTERS
- Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
- (2021) Timothy A. Yap et al. CLINICAL CANCER RESEARCH
- Novel and highly potent ATR inhibitor M4344 kills cancer cells with replication stress and enhances the chemotherapeutic activity of widely used DNA damaging agents
- (2021) Ukhyun Jo et al. MOLECULAR CANCER THERAPEUTICS
- Dynamics of replication origin over-activation
- (2021) Haiqing Fu et al. Nature Communications
- Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase
- (2021) Colin W. Garvie et al. Nature Communications
- Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
- (2021) Diana Zatreanu et al. Nature Communications
- THE MOLECULAR ANALYSIS FOR THERAPY CHOICE (NCI-MATCH) TRIAL: LESSONS for GENOMIC TRIAL DESIGN
- (2020) Keith T Flaherty et al. JNCI-Journal of the National Cancer Institute
- SLFN11 expression in advanced prostate cancer and response to platinum-based chemotherapy
- (2020) Vincenza Conteduca et al. MOLECULAR CANCER THERAPEUTICS
- BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers
- (2020) Florence Coussy et al. Science Translational Medicine
- Molecular profiling for precision cancer therapies
- (2020) Eoghan R. Malone et al. Genome Medicine
- CHK1 Inhibition Is Synthetically Lethal with Loss of B-Family DNA Polymerase Function in Human Lung and Colorectal Cancer Cells
- (2020) Rebecca F. Rogers et al. CANCER RESEARCH
- Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress
- (2020) Junko Murai et al. Cell Reports
- ATM-Deficient Cancers Provide New Opportunities for Precision Oncology
- (2020) Nicholas R. Jette et al. Cancers
- Human PCNA Structure, Function and Interactions
- (2020) Amaia González-Magaña et al. Biomolecules
- SLFN11 promotes stalled fork degradation that underlies the phenotype in Fanconi anemia cells
- (2020) Yusuke Okamoto et al. BLOOD
- BRCA1 mutations in cancer: coordinating deficiencies in homologous recombination with tumorigenesis
- (2020) John J. Krais et al. CANCER RESEARCH
- Review of precision cancer medicine: Evolution of the treatment paradigm
- (2020) Apostolia M. Tsimberidou et al. CANCER TREATMENT REVIEWS
- Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy
- (2020) John A. Hartley EXPERT OPINION ON BIOLOGICAL THERAPY
- Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors
- (2020) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial
- (2020) Panagiotis A Konstantinopoulos et al. LANCET ONCOLOGY
- The plasticity of DNA replication forks in response to clinically relevant genotoxic stress
- (2020) Matteo Berti et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Molecular Targeting of Cancer-Associated PCNA Interactions in Pancreatic Ductal Adenocarcinoma Using a Cell-Penetrating Peptide
- (2020) Shanna J. Smith et al. Molecular Therapy-Oncolytics
- A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies
- (2020) Sara M. Federico et al. EUROPEAN JOURNAL OF CANCER
- First-in-Human Trial of the Oral Ataxia Telangiectasia and Rad3-Related Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors
- (2020) Timothy A. Yap et al. Cancer Discovery
- SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures
- (2020) Camille Tlemsani et al. Cell Reports
- Harnessing DNA Replication Stress for Novel Cancer Therapy
- (2020) Huanbo Zhu et al. Genes
- PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
- (2020) Maddison Rose et al. Frontiers in Cell and Developmental Biology
- The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy
- (2020) Takuma Kagami et al. BMC CANCER
- The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response
- (2020) Niamh Coleman et al. BRITISH JOURNAL OF CANCER
- SLFN11 informs on standard of care and novel treatments in a wide range of cancer models
- (2020) Claudia Winkler et al. BRITISH JOURNAL OF CANCER
- Difficulties and challenges in the development of precision medicine
- (2019) Xiaoqin Liu et al. CLINICAL GENETICS
- Origin Firing Regulations to Control Genome Replication Timing
- (2019) Dominik Boos et al. Genes
- Genomic correlates of response to immune checkpoint blockade
- (2019) Tanya E. Keenan et al. NATURE MEDICINE
- Exploiting DNA Replication Stress for Cancer Treatment
- (2019) Tajinder Ubhi et al. CANCER RESEARCH
- Neddylation: a novel modulator of the tumor microenvironment
- (2019) Lisha Zhou et al. Molecular Cancer
- Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies
- (2019) Junko Murai et al. PHARMACOLOGY & THERAPEUTICS
- Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer
- (2019) Edoardo Isnaldi et al. BREAST CANCER RESEARCH AND TREATMENT
- Targeting Topoisomerase I in the Era of Precision Medicine
- (2019) Anish Thomas et al. CLINICAL CANCER RESEARCH
- Dormant origin signaling during unperturbed replication
- (2019) Tatiana N. Moiseeva et al. DNA REPAIR
- Replication-Coupled DNA Repair
- (2019) David Cortez MOLECULAR CELL
- Development of an Immunohistochemical Assay to Detect the Ataxia-Telangiectasia Mutated (ATM) Protein in Gastric Carcinoma
- (2019) Rachel M. Miller et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination–Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib
- (2019) Laetitia Marzi et al. CLINICAL CANCER RESEARCH
- Preparation for DNA Replication: The Key to a Successful S phase
- (2019) Juanita C. Limas et al. FEBS LETTERS
- Discovery of Inhibitors for Proliferating Cell Nuclear Antigen Using a Computational-Based Linked-Multiple-Fragment Screen
- (2019) Matthew D. Bartolowits et al. ACS Omega
- Dephosphorylation activates the interferon-stimulated Schlafen family member 11 in the DNA damage response
- (2019) Dane Malone et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancer models
- (2019) Antje M. Wengner et al. MOLECULAR CANCER THERAPEUTICS
- Functional genomic screen in mesothelioma reveals that loss of function of BRCA1-associated-protein-1 induces chemoresistance to ribonucleotide reductase inhibition
- (2019) Agata Okonska et al. MOLECULAR CANCER THERAPEUTICS
- Additive effects of a small molecular PCNA inhibitor PCNA-I1S and DNA damaging agents on growth inhibition and DNA damage in prostate and lung cancer cells
- (2019) Shan Lu et al. PLoS One
- WEE1 kinase inhibitor AZD1775 induces CDK1 kinase-dependent origin firing in unperturbed G1- and S-phase cells
- (2019) Tatiana N. Moiseeva et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?
- (2019) Alice Bradbury et al. PHARMACOLOGY & THERAPEUTICS
- Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers
- (2018) N J Birkbak et al. ANNALS OF ONCOLOGY
- A Small-Molecule Inhibitor of Human DNA Polymerase η Potentiates the Effects of Cisplatin in Tumor Cells
- (2018) Maroof K. Zafar et al. BIOCHEMISTRY
- Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11)Expression with Class I Histone Deacetylase Inhibitors
- (2018) Sai-Wen Tang et al. CLINICAL CANCER RESEARCH
- Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
- (2018) M. Catherine Pietanza et al. JOURNAL OF CLINICAL ONCOLOGY
- SLFN11 Blocks Stressed Replication Forks Independently of ATR
- (2018) Junko Murai et al. MOLECULAR CELL
- The emerging clinical relevance of genomics in cancer medicine
- (2018) Michael F. Berger et al. Nature Reviews Clinical Oncology
- Structure of Schlafen13 reveals a new class of tRNA/rRNA- targeting RNase engaged in translational control
- (2018) Jin-Yu Yang et al. Nature Communications
- Discovery of a novel DNA polymerase inhibitor and characterization of its antiproliferative properties
- (2018) Bhanvi Mishra et al. CANCER BIOLOGY & THERAPY
- DNA damage-induced cell death relies on SLFN11-dependent cleavage of distinct type II tRNAs
- (2018) Manqing Li et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer
- (2017) Alberto Ballestrero et al. Journal of Translational Medicine
- Replication Catastrophe: When a Checkpoint Fails because of Exhaustion
- (2017) Luis Toledo et al. MOLECULAR CELL
- ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response
- (2017) Andrew N. Blackford et al. MOLECULAR CELL
- Mechanisms of DNA replication termination
- (2017) James M. Dewar et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- The essential kinase ATR: ensuring faithful duplication of a challenging genome
- (2017) Joshua C. Saldivar et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay
- (2017) Jiuping Ji et al. PLoS One
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- The NCI-60 Methylome and Its Integration into CellMiner
- (2016) William C. Reinhold et al. CANCER RESEARCH
- PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
- (2016) Benjamin H. Lok et al. CLINICAL CANCER RESEARCH
- Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months
- (2016) Suzanne Leijen et al. JOURNAL OF CLINICAL ONCOLOGY
- Biochemical and cell biological assays to identify and characterize DNA helicase inhibitors
- (2016) Taraswi Banerjee et al. METHODS
- ETAA1 acts at stalled replication forks to maintain genome integrity
- (2016) Thomas E. Bass et al. NATURE CELL BIOLOGY
- Order from clutter: selective interactions at mammalian replication origins
- (2016) Mirit I. Aladjem et al. NATURE REVIEWS GENETICS
- Roles of eukaryotic topoisomerases in transcription, replication and genomic stability
- (2016) Yves Pommier et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Small cell lung cancer: Time to revisit DNA-damaging chemotherapy
- (2016) Anish Thomas et al. Science Translational Medicine
- Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
- (2016) Y. Pommier et al. Science Translational Medicine
- DNA Polymerases Divide the Labor of Genome Replication
- (2016) Scott A. Lujan et al. TRENDS IN CELL BIOLOGY
- Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
- (2016) Junko Murai et al. Oncotarget
- Non-human Primate Schlafen11 Inhibits Production of Both Host and Viral Proteins
- (2016) Alex C. Stabell et al. PLoS Pathogens
- Targeted Therapy for Cancer in the Genomic Era
- (2015) Anosheh Afghahi et al. CANCER JOURNAL
- SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma
- (2015) S.-W. Tang et al. CLINICAL CANCER RESEARCH
- SLFN11 inhibits checkpoint maintenance and homologous recombination repair
- (2015) Y. Mu et al. EMBO REPORTS
- Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial
- (2015) Ariel Lopez-Chavez et al. JOURNAL OF CLINICAL ONCOLOGY
- Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs
- (2015) Vanesa Nogales et al. Oncotarget
- A Small Molecule Inhibitor of Monoubiquitinated Proliferating Cell Nuclear Antigen(PCNA) Inhibits Repair of Interstrand DNA Cross-link, Enhances DNA Double Strand Break, and Sensitizes Cancer Cells to Cisplatin
- (2014) Akira Inoue et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Structural basis for inhibition of DNA replication by aphidicolin
- (2014) Andrey G. Baranovskiy et al. NUCLEIC ACIDS RESEARCH
- Molecular Analysis for Therapy Choice: NCI MATCH
- (2014) Barbara A. Conley et al. SEMINARS IN ONCOLOGY
- Ciprofloxacin is an inhibitor of the Mcm2-7 replicative helicase
- (2013) Nicholas Simon et al. BIOSCIENCE REPORTS
- Cullin-RING Ligases as Attractive Anti-cancer Targets
- (2013) Yongchao Zhao et al. CURRENT PHARMACEUTICAL DESIGN
- Roles of Chk1 in cell biology and cancer therapy
- (2013) Youwei Zhang et al. INTERNATIONAL JOURNAL OF CANCER
- The Schlafen Family of Proteins and Their Regulation by Interferons
- (2013) Evangelos Mavrommatis et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- Differential and Common DNA Repair Pathways for Topoisomerase I- and II-Targeted Drugs in a Genetic DT40 Repair Cell Screen Panel
- (2013) Y. Maede et al. MOLECULAR CANCER THERAPEUTICS
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Systematic identification of genomic markers of drug sensitivity in cancer cells
- (2012) Mathew J. Garnett et al. NATURE
- Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11
- (2012) Manqing Li et al. NATURE
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents
- (2012) G. Zoppoli et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- RNAi Screening Identifies TAK1 as a Potential Target for the Enhanced Efficacy of Topoisomerase Inhibitors
- (2011) S. E. Martin et al. CURRENT CANCER DRUG TARGETS
- Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer
- (2011) Gouji Toyokawa et al. Molecular Cancer
- Interfacial inhibitors: targeting macromolecular complexes
- (2011) Yves Pommier et al. NATURE REVIEWS DRUG DISCOVERY
- The BATTLE Trial: Personalizing Therapy for Lung Cancer
- (2011) Edward S. Kim et al. Cancer Discovery
- DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
- (2010) Yves Pommier et al. CHEMISTRY & BIOLOGY
- Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers
- (2010) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic instability — an evolving hallmark of cancer
- (2010) Simona Negrini et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Implication of Checkpoint Kinase-dependent Up-regulation of Ribonucleotide Reductase R2 in DNA Damage Response
- (2009) Yong-Wei Zhang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging
- (2009) Matilde Murga et al. NATURE GENETICS
- Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic Assay of Poly (ADP-Ribose) Polymerase in Tumor Biopsies of Mouse Xenografts
- (2008) R. J. Kinders et al. CLINICAL CANCER RESEARCH
- Nucleoside analogs: molecular mechanisms signaling cell death
- (2008) B Ewald et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now